Major Drug Approvals: Lilly and Eisai Gain NMPA Green Light for Migraine and Early Alzheimer’s Treatments

Jan 09, 2024 14:37 CST Updated 14:37

Jumpcan Pharmaceutical

National High-tech Enterprise

PHARSCIN PHARMA

Pharmaceutical Research, Production, and Sales

Shijiazhuang No.4 Pharmaceutical Co.,Ltd.

Manufacturers and Service Providers of Chemical Drugs and Traditional Chinese Medicine

Eli Lilly

Global Pharmaceutical R&D and Production Company

Eisai

Pharmaceutical Product R&D and Manufacturer

Novartis

Drug Development and Manufacturing

▲March 1-2 MAH&DDS Formulation Collaboration Conference ·Click to register now

Just now, NMPA released the information about the delivery of the drug approval certificate on January 9, 2024.This batch has 41 approval numbers granted, of which 12 are for consistency evaluation., including the following approved varieties:

JUMPCAN PHARMACEUTICAL GROUP CO.,LTD, Nimodipine Injection

Shandong New Time Pharmaceutical Co., Ltd., Decitabine for Injection

PHARSCIN PHARMA, Penehyclidine Hydrochloride Injection

Shijiazhuang No.4 Pharmaceutical Co.,Ltd., Chlorphenamine Maleate Injection

etc.

In addition,This time, 15 additional marketing application acceptance numbers have been approved., including:

Hubei Qijin Pharmaceutical Co.,Ltd.'s Ercha Shangqing Pills and Wuhan Kangle Pharmaceutical Co., Ltd.'s Shaoyao Gancao Granules, two new traditional Chinese medicine drugs, have been approved.

Eli Lilly's Galcanezumab Injection Approved for Marketing in China，The speculated indications are:For the preventive treatment of episodic migraine in adults.

Eisai's Leqembi Injection Approved for Marketing in China，For the treatment of early Alzheimer's disease (AD), namely AD-derived mild cognitive impairment (MCI) and mild AD dementia with confirmed amyloid pathology.

Novartis' Secukinumab Injection New Indication Approved for Marketing in ChinaThe indication for this approval has not been announced yet, but it was previously approved.Used for the treatment of adult psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, etc.

Welcome to add WeChat and join the Approval Family.

For communication only, unrelated to the official.